1
|
Mori T, Abe I. Lincosamide Antibiotics: Structure, Activity, and Biosynthesis. Chembiochem 2024; 25:e202300840. [PMID: 38165257 DOI: 10.1002/cbic.202300840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 12/29/2023] [Accepted: 01/02/2024] [Indexed: 01/03/2024]
Abstract
Lincosamides are naturally occurring antibiotics isolated from Streptomyces sp. Currently, lincomycin A and its semisynthetic analogue clindamycin are used as clinical drugs. Due to their unique structures and remarkable biological activities, derivatizations of lincosamides via semi-synthesis and biosynthetic studies have been reported. This review summarizes the structures and biological activities of lincosamides, and the recent studies of lincosamide biosynthetic enzymes.
Collapse
Grants
- JP20H00490 Ministry of Education, Culture, Sports, Science and Technology, Japan
- JP22H05126 Ministry of Education, Culture, Sports, Science and Technology, Japan
- JP23H00393 Ministry of Education, Culture, Sports, Science and Technology, Japan
- JP23H02641 Ministry of Education, Culture, Sports, Science and Technology, Japan
- JPNP20011 New Energy and Industrial Technology Development Organization
- JP21ak0101164 New Energy and Industrial Technology Development Organization
- JP23ama121027 New Energy and Industrial Technology Development Organization
- JPMJPR20DA Japan Science and Technology Agency
Collapse
Affiliation(s)
- Takahiro Mori
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
- Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan
- PRESTO, Japan Science and Technology Agency, 4-1-8, Honcho, Kawaguchi, Saitama, 332-0012, Japan
| | - Ikuro Abe
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
- Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan
| |
Collapse
|
2
|
Kumura K, Umemura E, Hirai Y, Ajito K. Discovery of Novel Lincomycin Derivatives Effective against Resistant Streptococcus pneumoniae and Streptococcus pyogenes Possessing ErmB Gene. J SYN ORG CHEM JPN 2022. [DOI: 10.5059/yukigoseikyokaishi.80.676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Ko Kumura
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd
| | | | | | | |
Collapse
|
3
|
Mason JD, Terwilliger DW, Pote AR, Myers AG. Practical Gram-Scale Synthesis of Iboxamycin, a Potent Antibiotic Candidate. J Am Chem Soc 2021; 143:11019-11025. [PMID: 34264649 DOI: 10.1021/jacs.1c03529] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
A gram-scale synthesis of iboxamycin, an antibiotic candidate bearing a fused bicyclic amino acid residue, is presented. A pivotal transformation in the route involves an intramolecular hydrosilylation-oxidation sequence to set the ring-fusion stereocenters of the bicyclic scaffold. Other notable features of the synthesis include a high-yielding, highly diastereoselective alkylation of a pseudoephenamine amide, a convergent sp3-sp2 Negishi coupling, and a one-pot transacetalization-reduction reaction to form the target compound's oxepane ring. Implementation of this synthetic strategy has provided ample quantities of iboxamycin to allow for its in vivo profiling in murine models of infection.
Collapse
Affiliation(s)
- Jeremy D Mason
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States
| | - Daniel W Terwilliger
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States
| | - Aditya R Pote
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States
| | - Andrew G Myers
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States
| |
Collapse
|
4
|
Synthesis and antibacterial activity of novel lincomycin derivatives. IV. Optimization of an N-6 substituent. J Antibiot (Tokyo) 2017; 70:1112-1121. [PMID: 29115289 DOI: 10.1038/ja.2017.143] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Revised: 10/07/2017] [Accepted: 10/07/2017] [Indexed: 11/08/2022]
Abstract
The design and synthesis of lincomycin derivatives modified at the C-6 and C-7 positions are described. A substituent at the C-7 position is a 5-aryl-1,3,4-thiadiazol-2-yl-thio group that generates antibacterial activities against macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes carrying an erm gene. An additional modification at the C-6 position was explored in application of information regarding pirlimycin and other related compounds. These dual modifications were accomplished by using methyl α-thiolincosaminide as a starting material. As a result of these dual modifications, the antibacterial activities were improved compared with those of compounds with a single modification at the C-7 position. The antibacterial activities of selected compounds in this report against macrolide-resistant S. pneumoniae and S. pyogenes with an erm gene were superior to those of telithromycin.
Collapse
|
5
|
Wakiyama Y, Kumura K, Umemura E, Masaki S, Ueda K, Sato Y, Hirai Y, Hayashi Y, Ajito K. Synthesis and SARs of novel lincomycin derivatives Part 5: optimization of lincomycin analogs exhibiting potent antibacterial activities by chemical modification at the 6- and 7-positions. J Antibiot (Tokyo) 2017; 71:298-317. [DOI: 10.1038/ja.2017.114] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2017] [Revised: 08/15/2017] [Accepted: 08/24/2017] [Indexed: 11/09/2022]
|
6
|
Kumura K, Wakiyama Y, Ueda K, Umemura E, Watanabe T, Yamamoto M, Yoshida T, Ajito K. Synthesis and antibacterial activity of novel lincomycin derivatives. III. Optimization of a phenyl thiadiazole moiety. J Antibiot (Tokyo) 2017; 71:ja201759. [PMID: 28676716 DOI: 10.1038/ja.2017.59] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2017] [Revised: 04/09/2017] [Accepted: 04/21/2017] [Indexed: 11/08/2022]
Abstract
Lincomycin derivatives that have a 5-(2-nitrophenyl)-1,3,4-thiadiazol-2-yl thio moiety at the 7-position were synthesized. 5-Substituted 2-nitrophenyl derivatives showed potent antibacterial activities against Streptococcus pneumoniae and Streptococcus pyogenes with erm gene. Antibacterial activities of the 4,5-di-substituted 2-nitrophenyl derivatives were generally comparable to those of telithromycin (TEL) against S. pneumoniae with erm gene and clearly superior to those of TEL against S. pyogenes with erm gene. Compounds 6 and 10c that have a methoxy group at the 5-position of the benzene ring exhibited activities comparable to TEL against Haemophilus influenzae. These results suggest that lincomycin derivatives modified at the 7-position would be promising compounds as a clinical candidate. We would like to dedicate this article to the special issue for late Professor Dr. Hamao Umezawa in The Journal of Antibiotics.The Journal of Antibiotics advance online publication, 5 July 2017; doi:10.1038/ja.2017.59.
Collapse
Affiliation(s)
- Ko Kumura
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Yoshinari Wakiyama
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Kazutaka Ueda
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Eijiro Umemura
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Takashi Watanabe
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Mikio Yamamoto
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Takuji Yoshida
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Keiichi Ajito
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| |
Collapse
|
7
|
Wakiyama Y, Kumura K, Umemura E, Ueda K, Watanabe T, Yamada K, Okutomi T, Ajito K. Synthesis and structure–activity relationships of novel lincomycin derivatives. Part 4: synthesis of novel lincomycin analogs modified at the 6- and 7-positions and their potent antibacterial activities. J Antibiot (Tokyo) 2017; 70:888-906. [DOI: 10.1038/ja.2017.54] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 03/20/2017] [Indexed: 11/09/2022]
|
8
|
Synthesis and antibacterial activity of novel lincomycin derivatives. II. Exploring (7S)-7-(5-aryl-1,3,4-thiadiazol-2-yl-thio)-7-deoxylincomycin derivatives. J Antibiot (Tokyo) 2016; 70:655-663. [DOI: 10.1038/ja.2016.139] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Revised: 09/25/2016] [Accepted: 10/23/2016] [Indexed: 12/15/2022]
|
9
|
Synthesis and structure-activity relationships of novel lincomycin derivatives part 3: discovery of the 4-(pyrimidin-5-yl)phenyl group in synthesis of 7(S)-thiolincomycin analogs. J Antibiot (Tokyo) 2016; 70:52-64. [PMID: 27703159 DOI: 10.1038/ja.2016.114] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2016] [Revised: 07/31/2016] [Accepted: 08/05/2016] [Indexed: 11/08/2022]
Abstract
Novel lincomycin derivatives possessing an aryl phenyl group or a heteroaryl phenyl group at the C-7 position via sulfur atom were synthesized by Pd-catalyzed cross-coupling reactions of 7(S)-7-deoxy-7-thiolincomycin (5) with various aryl halides. This reaction is the most useful method to synthesize a variety of 7(S)-7-deoxy-7-thiolincomycin derivatives. On the basis of analysis of structure-activity relationships of these novel lincomycin derivatives, we found that (a) the location of basicity in the C-7 side chain was an important factor to enhance antibacterial activities, and (b) compounds 22, 36, 42, 43 and 44 had potent antibacterial activities against a variety of Streptococcus pneumoniae with erm gene, which cause severe respiratory infections, even compared with our C-7-modified lincomycin analogs (1-4) reported previously. Furthermore, 7(S)-configuration was found to be necessary for enhancing antibacterial activities from comparison of configurations at the 7-position of 36 (S-configuration) and 41 (R-configuration).
Collapse
|
10
|
Wakiyama Y, Kumura K, Umemura E, Masaki S, Ueda K, Watanabe T, Yamamoto M, Hirai Y, Ajito K. Synthesis and structure-activity relationships of novel lincomycin derivatives. Part 2. Synthesis of 7(S)-7-deoxy-7-(4-morpholinocarbonylphenylthio)lincomycin and its 3-dimensional analysis with rRNA. J Antibiot (Tokyo) 2015; 69:428-39. [PMID: 26669751 DOI: 10.1038/ja.2015.125] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2015] [Revised: 11/02/2015] [Accepted: 11/12/2015] [Indexed: 11/09/2022]
Abstract
Lincomycin derivatives, which possess a hetero ring at the C-7 position via sulfur atom, were synthesized by three types of reactions: (1) Mitsunobu reaction of 2,3,4-tris-O-(trimethylsiliyl)lincomycin (1) with the corresponding thiol, (2) SN2 reaction of 7-O-methanesulfonyl-2,3,4-tris-O-(trimethylsiliyl)lincomycin (2) with the corresponding thiol and (3) Pd-catalyzed cross-coupling reaction of 7-deoxy-7-epi-7-mercaptolincomycin (35) with the corresponding aryl halides. As a result, compound 28 had potent antibacterial activities against major pathogens, which caused respiratory infections, even compared with clindamycin. On the other hand, compound 38 showed most potent activities against a variety of Streptococcus pneumoniae with erm gene.
Collapse
Affiliation(s)
- Yoshinari Wakiyama
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | - Ko Kumura
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | - Eijiro Umemura
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | - Satomi Masaki
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | - Kazutaka Ueda
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | - Takashi Watanabe
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | - Mikio Yamamoto
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | - Yoko Hirai
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | - Keiichi Ajito
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| |
Collapse
|